MA37437B1 - Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement - Google Patents

Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement

Info

Publication number
MA37437B1
MA37437B1 MA37437A MA37437A MA37437B1 MA 37437 B1 MA37437 B1 MA 37437B1 MA 37437 A MA37437 A MA 37437A MA 37437 A MA37437 A MA 37437A MA 37437 B1 MA37437 B1 MA 37437B1
Authority
MA
Morocco
Prior art keywords
choice
status
treatment
her2 protein
breast cancer
Prior art date
Application number
MA37437A
Other languages
English (en)
Other versions
MA37437A1 (fr
Inventor
El Hassane Sefrioui
Abdeladim MOUMEN
El Amrani Manal
Imane Abdellaoui-Maane
Hadi Hicham El
Original Assignee
Mascir (Morrocan Found For Advanced Science Innovation & Research)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mascir (Morrocan Found For Advanced Science Innovation & Research) filed Critical Mascir (Morrocan Found For Advanced Science Innovation & Research)
Priority to MA37437A priority Critical patent/MA37437B1/fr
Priority to PCT/MA2015/000018 priority patent/WO2016060536A1/fr
Publication of MA37437A1 publication Critical patent/MA37437A1/fr
Publication of MA37437B1 publication Critical patent/MA37437B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un kit de diagnostic in vitro pour la quantification des transcrits du gène her2 surexprimé dans le cas du cancer du sein et de l’estomac ainsi que dans d’autres types de cancers. Le présent kit est composé d’une combinaison innovante de nouveaux sets d’amorces et de sondes permettant la détection spécifique et la quantification des transcrits du gène her2 et les gènes de référence, choisis parmi les gènes rpl30 ou rpl37 ou bien mrpl19 en utilisant la méthode de transcription inverse-pcr en temps réel (rtqpcr) en format multiplexe ou simplexe. Le présent kit est destiné pour l’établissement du statut de la protéine her2 et le choix du traitement pour le cancer de sein ou tout cancer nécessitant une quantification de la protéine her2.
MA37437A 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement MA37437B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MA37437A MA37437B1 (fr) 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement
PCT/MA2015/000018 WO2016060536A1 (fr) 2014-10-17 2015-10-17 Kit de diagnostic du cancer de sein en reaction qpcr multiplex et son application dans l'evaluation du statut de la proteine her2 et le choix du traitement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA37437A MA37437B1 (fr) 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement

Publications (2)

Publication Number Publication Date
MA37437A1 MA37437A1 (fr) 2016-05-31
MA37437B1 true MA37437B1 (fr) 2016-12-30

Family

ID=55273425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37437A MA37437B1 (fr) 2014-10-17 2014-10-17 Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement

Country Status (2)

Country Link
MA (1) MA37437B1 (fr)
WO (1) WO2016060536A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41742B1 (fr) * 2017-12-29 2020-02-28 Moroccan Foundation For Advanced Science Innovation And Res Mascir Méthode pour la détermination du seuil de positivité de la surexpression de la protéine her2 dans le cancer de sein et d'autres cancers.
RU2701356C1 (ru) * 2018-09-18 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Способ диагностики рака молочной железы с экспрессией рецептора Her2/neu на мембране опухолевых клеток
CN110616251B (zh) * 2019-09-29 2022-08-05 中国计量科学研究院 一种用于检测乳腺癌her2拷贝数变异的数字pcr方法及检测试剂盒
CN117995279B (zh) * 2024-04-03 2024-06-18 四川大学华西医院 不同pcr仪器间定量或定性检测结果同质化换算方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA35294B1 (fr) * 2012-12-27 2014-08-01 Mascir Moroccan Foundation For Advanced Science Innovation & Res Sondes et amorces pour detecter le gene her2 en format multiplexe et ses applications dans le choix du traitement du cancer de sein her2

Also Published As

Publication number Publication date
WO2016060536A1 (fr) 2016-04-21
MA37437A1 (fr) 2016-05-31

Similar Documents

Publication Publication Date Title
Yuwen et al. Prognostic role of circulating exosomal miR-425-3p for the response of NSCLC to platinum-based chemotherapy
Papantonis et al. TNFα signals through specialized factories where responsive coding and miRNA genes are transcribed
Knuuttila et al. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model
Ismail et al. Diagnostic significance of miR-639 and miR-10b in βreast cancer patients
MA37437B1 (fr) Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement
AU2003294447A8 (en) Preparation and use of single-stranded transcription substrates for synthesis of transcription products corresponding to target sequences
MX2017014859A (es) Metodos y composiciones para diagnosticar o detectar canceres de pulmon.
Ning et al. Characterization of the Merkel cell carcinoma miRNome
JP2016533742A (ja) Ｄｏｔ１ｌ阻害に反応する白血病の検出および治療方法
EP4435112A3 (fr) Compositions et procédés de criblage de tumeurs solides
Liu et al. Kaiso interacts with p120-catenin to regulate β-catenin expression at the transcriptional level
Adam-Artigues et al. Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
Kaehler et al. MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells
Carozzo et al. Identification of MRP4/ABCC4 as a target for reducing the proliferation of pancreatic ductal adenocarcinoma cells by modulating the cAMP efflux
Ravid et al. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures
MX2019011017A (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii.
Li et al. Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis
Hong et al. TP53-induced glycolysis and apoptosis regulator protects from spontaneous apoptosis and predicts poor prognosis in chronic lymphocytic leukemia
Fasihi et al. Hsa-miR-942 fingerprint in colorectal cancer through Wnt signaling pathway
Hamborg et al. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma
Tang et al. Aberrant high expression of NRG1 gene in Hirschsprung disease
Baykara et al. CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC)
CA2978368A1 (fr) Signature de la sante
Wang et al. Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas
Shehata et al. LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients